Decitabine (NSC 127716)

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

For research use only.

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Decitabine (NSC 127716) Chemical Structure

CAS No. 2353-33-5

Selleck's Decitabine (NSC 127716) has been cited by 119 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MVTGeY5kfGmxbjDBd5NigQ>? MmGyNE42yqEQvF2= NHK0PZEzPCCq Mmfwe4F1\XJ? NWLsZ4o3dW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? M{XwN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonMNE42NzJwNT:1JO69VQ>? MmfFNlQwPDhxN{KgbC=> NVjZO3c3f2G2ZYK= NUGwTWdLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MnXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 MXvGeY5kfGmxbjDBd5NigQ>? MV2wMlXDqM7:TR?= NXfYZplwPi9zMj:yOEBp NUnCfpVlf2G2ZYK= MXPpcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi MmPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 MnTXSpVv[3Srb36gRZN{[Xl? NIHNd5QxNjYEoN88US=> NXPnbnI4OjRiaB?= MVL3ZZRmeg>? NV;iWYRWcW6qaXLpeJMh[2WubDDpcpZie2mxbh?= NUT1N|AxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT4NE42yqEQvF2= MWiyOEBp Mo\pe4F1\XJ? MVvpcoR2[2W|IFeyM20h[XK{ZYP0JIlvKHSqZTDj[YxtKGO7Y3zl MnXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 NX[1UIwyTnWwY4Tpc44hSXO|YYm= NIiyZ4UxNjVxMTFOwG0> NIDXXHEzPCCq MXH3ZZRmeg>? MWnk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz NGPTe5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
SW1116  NXHWWI4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TGNlAvPS9zL{KvOUDPxE1? M3XjdFQ5KGh? NYf1VlhmTE2VTx?= MX3lcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NHXMUWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
LOVO NXvx[YVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETqR2MxNjVxMT:yM|Uh|ryP M3fJPVQ5KGh? NI\FdGNFVVOR MofP[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
SW1116  NUj0bmZwTnWwY4Tpc44hSXO|YYm= MnLONVAh|ryP NVG4NHFEPDhiaB?= M2[2V2ROW09? NH;uO|NqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? NVmwdHBORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|QzQDZpPkK0PFc1Ojh4PD;hQi=>
LOVO MUjGeY5kfGmxbjDBd5NigQ>? MWexNEDPxE1? NYO4[5lXPDhiaB?= MljQSG1UVw>? NIH2WWNqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? Mlm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
SW1116  MorwRZBweHSxc3nzJGF{e2G7 MmToNVAh|ryP MUW0PEBp Moj2SG1UVw>? MlTl[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NIfsdHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
LOVO MkDTRZBweHSxc3nzJGF{e2G7 MVuxNEDPxE1? M{fmcVQ5KGh? NGfhRoNFVVOR MVHlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= M1rUZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
RPMI-8226 NX\x[WVISXCxcITvd4l{KEG|c3H5 MnzONU8zKM7:TR?= MUW0PE84Oi97NjDo NXnMUpJITE2VTx?= MVzpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
OPM-2  M2LGTmFxd3C2b4Ppd{BCe3OjeR?= Mo\ZNU8zKM7:TR?= NGPDW3k4Oi97Nj:xNlAhcA>? NVnId2RXTE2VTx?= NFXXSZpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4DJRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
JJN3  MUnBdI9xfG:|aYOgRZN{[Xl? NELGSWMxNjVxMTFOwG0> Mn;RNlQwPDhiaB?= NUi5RVc1TE2VTx?= Ml7ibY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NIC2[Yo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
NCI-H929  MVXBdI9xfG:|aYOgRZN{[Xl? MWCxM|Ih|ryP NFi1c4s4Oi97Nj:xNlAhcA>? NXjqRplDTE2VTx?= NYnITlNtcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M1LKUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
RPMI-8226 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[xM|Ih|ryP M4S2[FI1NzR6L{eyJIg> M2fs[2ROW09? NEDFWG9i\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MlXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{OxNFgoRjJ2OEOzNVA5RC:jPh?=
OPM-2  NHvyXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7HNU8zKM7:TR?= MmDyNlQwPDhxN{KgbC=> MorqSG1UVw>? MVfh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? M1zHTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
JJN3  M1\DTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmwMlUwOSEQvF2= MWOyOE81QC95MjDo NHjiR5FFVVOR NHnVem1i\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NEe0Ro09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
NCI-H929  NWewTIRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexM|Ih|ryP NXy2WVVkOjRxNEivO|IhcA>? MmrFSG1UVw>? MXPh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NEKzW5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
HeLa NWfx[GJJU2mwYYPlJGF{e2G7 Mkj5T4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6MEC5PEc,OjR5OECwPVg9N2F-
HeLa NV[zUXR4U2mwYYPlJGF{e2G7 MkPLT4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy M3L1d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
HeLa M4HzPGtqdmG|ZTDBd5NigQ>? M1;uNmtqRTJzLk[gxtEhOy5yIN88UUBnd3JiaFPOWFE> M1jjeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
HeLa MnzLT4lv[XOnIFHzd4F6 MUHLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz MknoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
NB4 NV65RYxSTnWwY4Tpc44hSXO|YYm= MkLNNk42NzVxNz61M|ExKM7:TR?= Mn6yNlQhcA>? M{jC[WROW09? MV3pcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh NXfPfpNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFQ5PzBpPkK0OFg1QDdyPD;hQi=>
CD4+ CD25− T  M2HCUmZ2dmO2aX;uJGF{e2G7 NWC5NpZ1OS93IN88US=> MUTy[YR2[2WVIHfsc4JidCCGTlGgcYV1cHmuYYTpc44> NHLaWGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3OlM3OCd-MkS0O|Y{PjB:L3G+
BV-173 MXnBdI9xfG:|aYOgRZN{[Xl? M3uwNFAvOjVxMD61M|AvPzVxMTFOwG0> M1XD[VQ5Nzd{L{m2JIg> NFfSNm3DqFCEUx?= NFj4[|VqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NWTSUFNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
ML-1 Mn;KRZBweHSxc3nzJGF{e2G7 M3jVd|AvOjVxMD61M|AvPzVxMTFOwG0> MlTaOFgwPzJxOU[gbC=> MkTjxsBRSlN? NVrRT3YycW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60 MlOyRZBweHSxc3nzJGF{e2G7 NU\UeIFGOC5{NT:wMlUwOC55NT:xJO69VQ>? MkjwOFgwPzJxOU[gbC=> NWnLfFVlyqCSQmO= MmTYbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M3uzPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
KG-1a M{nVSWFxd3C2b4Ppd{BCe3OjeR?= NYTncIpSOC5{NT:wMlUwOC55NT:xJO69VQ>? Mo\BOFgwPzJxOU[gbC=> MXVCpHBDWw>? M1PsOolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M4HMc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
BV-173 NH:2eHRHfW6ldHnvckBCe3OjeR?= M{LQWFI2OC93MEDuUS=> MYW0PEBp M1fHXuKhWEKV MXXpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? Mke3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
CEM NEWwRodHfW6ldHnvckBCe3OjeR?= MlTKNlUxNzVyMH7N M3LGTFQ5KGh? MYpCpHBDWw>? NWC1U|VrcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NH3Zfm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
HL-60 NX\rXZdsTnWwY4Tpc44hSXO|YYm= MorFNlUxNzVyMH7N MoqxOFghcA>? NXvnV|ZsyqCSQmO= NWPsWXU{cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl M1zne|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
ML-1 NY\xVZh3TnWwY4Tpc44hSXO|YYm= M{nkUlI2OC93MEDuUS=> NVS1fXhOPDhiaB?= M1\LT:KhWEKV M{LSfolv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
DLD-1 MYDGeY5kfGmxbjDBd5NigQ>? M{HYdVI2OC93MEDuUS=> M4e3cVQ5KGh? NV3GVVJjyqCSQmO= MYrkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm M2TxRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
HCT-116 NIjnXmhHfW6ldHnvckBCe3OjeR?= MVyyOVAwPTBybl2= NVy0bHVPPDhiaB?= MVlCpHBDWw>? MkHP[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? NWXRc41VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
U937-A/E-9/14/18  M1nEWGFxd3C2b4Ppd{BCe3OjeR?= NED3bHYxNjBzL{CuNU8yNzFyIN88US=> M13UN|Q5KGh? NWXsdJZOcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NY[wRotMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNFA1PTZpPkK0N|AxPDV4PD;hQi=>
HT29 NXTH[oMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;Ie|czKGh? NIrWN2NKSzVyPUG0NFDDuTF5OTFOwG0> NHnvSGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NlA3OSd-MkSxO|IxPjF:L3G+
SW48 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLrO|IhcA>? NIrWUlVKSzVyPUG1MlLDuTZwMjFOwG0> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MkC2NUc,OjRzN{KwOlE9N2F-
HCT116 NGjr[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rleFczKGh? MnvxTWM2OD1zLkhCtVAvPCEQvF2= NIrCU3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NlA3OSd-MkSxO|IxPjF:L3G+
HepG2 MnKySpVv[3Srb36gRZN{[Xl? M4fU[FAvPS9zIN88US=> NWe3dWM{OjRiaB?= MVPEUXNQ M3zmVJVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
LS174T MnfWSpVv[3Srb36gRZN{[Xl? M2ryPVAvPS9zIN88US=> MV6yOEBp NV3WNZV[TE2VTx?= MWns[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
HepG2 MoX0RZBweHSxc3nzJGF{e2G7 NWLUXXdKOS9zMD:xNFAh|ryP M4G5R|ch\A>? M3PY[2ROW09? NWDWTo5JcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1naN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
LS174T MoLORZBweHSxc3nzJGF{e2G7 M3nBNVEwOTBxMUCwJO69VQ>? M1HoVlch\A>? NXf1dVZVTE2VTx?= MmSzbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXjUPYpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
QBC-939 NF7mUmFCeG:ydH;zbZMhSXO|YYm= MW[xM|ExNzFyMDFOwG0> M{HxR|ch\A>? NGjudVVFVVOR MXLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NF7RWlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
U251 NUHtbGUxSXCxcITvd4l{KEG|c3H5 NGe0dWgyNzFyL{GwNEDPxE1? NFHiUWc4KGR? M4nDdGROW09? NGXlTnZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
HL-60 NVLiPVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\uNUDPxE1? NFHk[Xc1QCCq M1PrR4lv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w M2nKclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MECwN|I1Lz5{NECwNFMzPDxxYU6=
MDA‑MB‑453 NHvzWnVHfW6ldHnvckBCe3OjeR?= MnTMNE4zNzFizszN NGjWNYo4OiCq M4LDfYNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NFjPdGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFIzQCd-MkO4OFQzOjh:L3G+
HCC1569 MXjGeY5kfGmxbjDBd5NigQ>? NV3VV4FzOC5{L{Gg{txO NWTJWW5bPzJiaB?= Ml7vZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NEKyPEc,OjN6NESyNlg9N2F-
BT‑474 NWTVWZlnTnWwY4Tpc44hSXO|YYm= Mk[3NE4zNzFizszN MnvqO|IhcA>? NWrnbWx5[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NFfsPXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFIzQCd-MkO4OFQzOjh:L3G+
AGS NFfPSlFCeG:ydH;zbZMhSXO|YYm= Mny0OU8yOC9{MD:1NEDPxE1? M1rUe|Q5yqCqwrC= MnzkSG1UVw>? NYPwe206cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? MnHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ|NUiyO|g1RC:jPh?=
A549 MoTHRZBweHSxc3nzJGF{e2G7 NHvxSGg2NzFyL{KwM|UxKM7:TR?= MXe0POKhcMLi NFXq[|hFVVOR NH7tV|lqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? MmjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ|NUiyO|g1RC:jPh?=
AGS  M3jmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPUeotYPS9zMD:yNE82OCEQvF2= NGLORok1QMLiaNMg MXHEUXNQ M1S2W4lv\HWlZYOgS|IwVSCyaHHz[UBienKnc4VCpC=> MorUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ|NUiyO|g1RC:jPh?=
Kasumi-1 M4DPfmFxd3C2b4Ppd{BCe3OjeR?= MXmwMlUh|ryP MXS0POKhcMLi NYfkOFNl\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MnzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ|NEmzN|Q5RC:jPh?=
OCI-AML3 NEPDbldCeG:ydH;zbZMhSXO|YYm= NWXHU2wyOi53IN88US=> Mlv6OFjDqGkEoB?= NWjWeXJZ\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NFfVTGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5N|M1QCd-MkO0PVM{PDh:L3G+
MV4-11 NGmzXmpCeG:ydH;zbZMhSXO|YYm= M2rySlIvPSEQvF2= MW[0POKhcMLi NFXzfYhl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> M1r4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEmzN|Q5Lz5{M{S5N|M1QDxxYU6=
NK  M3vVbGN6fG:2b4jpeJkhSXO|YYm= M1PiWFAvODJvMkCg{txO NEHwR3I2KGR? Mn3o[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? NYDtb|JIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNlgxQDhpPkKzN|I5ODh6PD;hQi=>
NK  MVTBdI9xfG:|aYOgRZN{[Xl? MorSNE4xOi1{MDFOwG0> NHnsRpM2KGR? MmjL[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl NIr3S2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
NK  MWLGeY5kfGmxbjDBd5NigQ>? NFH0eYwxNjBzLUKwJO69VQ>? NYTndFBYPSCm M1vVd4NifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> M{fST|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{K4NFg5Lz5{M{OyPFA5QDxxYU6=
MOLT4/DNR NH\6ZoJHfW6ldHnvckBCe3OjeR?= Mm\DOUDPxE1? MVS0JIQ> NUfYdWw{emWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? M3ewc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
Jurkat/DOX MonZSpVv[3Srb36gRZN{[Xl? M3zaNVUh|ryP NFLofWQ1KGR? NWjVbZB5emWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? Mn;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O|AoRjJ|ME[wOVcxRC:jPh?=
MOLT4/DNR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;pVZI2KM7:TR?= NWLDdnAzPCCm NXLvS49yemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> NWK4UY9IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
Jurkat/DOX M{LVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LTTFUh|ryP MnT0OEBl M4HrdJJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= NUj0UZBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
ccRCC  NW\ISZk4SXCxcITvd4l{KEG|c3H5 M2nFXFAvODFvMUFOwG0> NG\1cGQ4OiCq MYrEUXNQ NYfWc4dQcGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= NGLWN4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
TNBC  MUDBdI9xfG:|aYOgRZN{[Xl? NHOxNm0xNjBzLUGw{txO NGDsOmU4OiCq NWrQb4s4TE2VTx?= MYXoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NW\0bmZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
A498 NV[4elhiSXCxcITvd4l{KEG|c3H5 Mlv2NE4xOS1zMN88US=> MoTLO|IhcA>? NFHKN2FFVVOR NIPOeIFqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MmXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Mk[0OlcoRjJ{OEK2OFY4RC:jPh?=
KIJ265T NFvIRo1CeG:ydH;zbZMhSXO|YYm= NH3zWGcxNjBzLUGw{txO MVG3NkBp NXWxN3RDTE2VTx?= MYPpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NUDYcJF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
MDA-231 NInxZmNCeG:ydH;zbZMhSXO|YYm= M321dVAvODFvMUFOwG0> NVvUfYRJPzJiaB?= MmDISG1UVw>? MWnpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NYX0[ZZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
BT-20 NX\lfoNsSXCxcITvd4l{KEG|c3H5 MUewMlAyNTFyzszN MYq3NkBp M2LDbmROW09? MmHnbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M{GzdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
U937 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfGXY5RPS1{MDFOwG0> M2XPSlI1NzR6L{eyJIg> NXPEXFBjcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60 M1zZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe1MVIxKM7:TR?= MVGyOE81QC95MjDo M2fKR4lv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MmXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NkewNlEoRjJ{N{[3NFIyRC:jPh?=
U937 NFLGfnBCeG:ydH;zbZMhSXO|YYm= MmfuNVUh|ryP M2ThcFI1NzR6L{eyJIg> MmjxbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NIr1[2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2O|AzOSd-MkK3OlcxOjF:L3G+
HL60 NWPVTXJnSXCxcITvd4l{KEG|c3H5 NXrQcm5sOTVizszN MYqyOE81QC95MjDo M4[we4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
LS411N  Ml\mRZBweHSxc3nzJGF{e2G7 NF3Te2YxNjVizszN Mke0O|IhcA>? MmTQbY5kemWjc3XzJGZieyCvUl7BJIxmfmWu MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR4MU[5OUc,OjJ2NkG2PVU9N2F-
MDA-MB-231 NWjsfoVmSXCxcITvd4l{KEG|c3H5 NETINZgyOCEQvF2= MYe0PEBp NEPQWXpz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{DlXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi3Olk4Lz5{MUi4O|Y6PzxxYU6=
MCF-7  M4LzU2Fxd3C2b4Ppd{BCe3OjeR?= MnnQNVAh|ryP M3iwRlQ5KGh? NFrESI5z\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVjoN3k1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFc3QTdpPkKxPFg4Pjl5PD;hQi=>
A375 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjZOosxNjVizszN M2ni[VEwPS96IHS= NH30d|VqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M1;iU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
SKMEL1 NFPIZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmwMlUh|ryP NY\acY46OS93L{ig[C=> MW\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NXzT[W5JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO|k3PjJ{PD;hQi=>
SKMEL3 NInuR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\DeGUxNjVizszN M2HwWFEwPS96IHS= MYPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL28 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWOxUJRTOC53IN88US=> MYqxM|UwQCCm NH:2T4tqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
MeWo NEDlNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XlVVAvPSEQvF2= MXmxM|UwQCCm MVXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M1nCSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
B16 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\uZoMxNjVizszN NHi0XW8yNzVxODDk Mli0bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M2fSXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
Ly 1 NVXGcZVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ixOFI1KGh? NXjvPGxuUUN3ME23MlMh|ryP M3vj[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 M2fRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmyOEBp MV7JR|UxRTFyLkeg{txO M2OwelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL6 NGXSb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHYU4IzPCCq M1XNdmlEPTExvK6yNEDPxE1? NWn5WVd1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjpSFlSOjRiaB?= MYDJR|Ux97zgMkCg{txO NYfsZlVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA M2fsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPMdmtrOjRiaB?= NWTWVFRPUUN3MP-8olIxKM7:TR?= NVHTRY03RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Su-DHL2 NYPJ[5FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;YVHRGOjRiaB?= NFi1T4lKSzVy78{eNlAh|ryP NF;s[Yo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 1 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzIdZpoPDhiaB?= M4Dq[mlEPTB;MD6zOEDPxE1? M17DWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq0PEBp NWe0cppHUUN3ME2wMlAzPSEQvF2= M1TGPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL6 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXIfVVMPDhiaB?= Mm\HTWM2OO,:nkKwJO69VQ>? NWPJS5lLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 10 MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;D[|lXPDhiaB?= NH7ud29KSzVyPUGuPEDPxE1? NU\KUWJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA NWnhUXZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELjeWM1QCCq M4\HUGlEPTExvK6yNEDPxE1? MnPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL2 NEXNd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe0PEBp MXnJR|UxRTF5LkSg{txO MnLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 1 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi2O|IhcA>? NFTz[4hKSzVyPUCuNFEh|ryP M1vvdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7 NIDL[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\uSnZLPzJiaB?= NVm2RWlQUUN3ME2wMlAyQCEQvF2= Mn[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL6 NXn6dlNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnMZXFsPzJiaB?= NWfUT3AyUUN3ME2xMlYh|ryP NVvPRoJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnThO|IhcA>? MVLJR|UxRTFwMjFOwG0> M13TRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV23NkBp M1rCZWlEPTExvK6yNEDPxE1? NH3OZYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL2 NIDPXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly1O|IhcA>? NWXlfpo5UUN3ME2xNU4zKM7:TR?= M2j3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
U373-MAGI M3\Ue2FvfGm4aYLhcEBie3OjeR?= M{X0W|AvOjVidH:gPEB2VQ>? M1S4N|IhfG9iN{KgbJJ{ NHHmUoVCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBXW1ZvRzDwd4V2\G:2eYDl[EBJUVZvMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHU2NWejZzDs[ZZmdCCjdDCwMlI2KHSxIEigeW0h[W[2ZYKgNkB1dyB5MjDodpMh[nlicWDDVkBu\XSqb3S= M3L3O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI NVWzdnVxSW62aY\pdoFtKGG|c3H5 M3jkXFAvOjVidH:gPEB2VQ>? NED4N5AzKHSxIEeyJIhzew>? NILWdmFCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBXW1ZvRzDwd4V2\G:2eYDl[EBJUVZvMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJIdi\yCuZY\lcEBifCByLkK1JJRwKDhidV2gZYZ1\XJiMjD0c{A4OiCqcoOgZpkheVCFUjDt[ZRpd2R? M4D4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
Assay
Methods Test Index PMID
Western blot Survivin / Bcl-2 / p53 / c-Myc / DNMT1 ; p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN ; phospho-p38 / p38 / phospho-NFκB / NFκB ; p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax 26384351 25762617 26617834 26692933 28152502
Immunofluorescence DNMT1 ; E-cadherin / MMP-9 21303982 28152502
Growth inhibition assay Cell viability 26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol (from reference)

Kinase Assay:[1]
  • DNA synthesis assay :

    The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.

Cell Research:[1]
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
  • (Only for Reference)
Animal Research:[2]
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 45 mg/mL
(197.18 mM)
Water 10 mg/mL warmed
(43.81 mM)
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.

10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04985656 Withdrawn Drug: Pevonedistat|Drug: Decitabine|Drug: Cedazuridine Myelodysplastic Syndromes (MDS) Takeda October 1 2021 Phase 2
NCT04854889 Recruiting Drug: Decitabine Refractory Aplastic Anemia Institute of Hematology & Blood Diseases Hospital April 22 2021 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?

Answer:
S1200 is R form

Tags: buy Decitabine (NSC 127716) | Decitabine (NSC 127716) supplier | purchase Decitabine (NSC 127716) | Decitabine (NSC 127716) cost | Decitabine (NSC 127716) manufacturer | order Decitabine (NSC 127716) | Decitabine (NSC 127716) distributor